TG Therapeutics (NASDAQ:TGTX) Given "Overweight" Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of TG Therapeutics (NASDAQ:TGTX - Free Report) in a report issued on Thursday, Benzinga reports. The firm currently has a $25.00 price target on the biopharmaceutical company's stock.

Several other analysts also recently issued reports on TGTX. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a neutral rating in a report on Thursday, February 29th. StockNews.com downgraded shares of TG Therapeutics from a buy rating to a hold rating in a report on Saturday, February 24th. B. Riley increased their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a buy rating in a report on Monday, February 5th. Finally, HC Wainwright reissued a buy rating and issued a $45.00 price target on shares of TG Therapeutics in a report on Thursday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, TG Therapeutics presently has an average rating of Moderate Buy and an average target price of $29.00.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX traded up $0.17 during trading hours on Thursday, hitting $13.99. 3,483,750 shares of the stock were exchanged, compared to its average volume of 4,195,929. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The company's 50 day moving average is $15.14 and its 200 day moving average is $13.87. The firm has a market capitalization of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. The business had revenue of $43.97 million during the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same period in the prior year, the firm earned ($0.39) EPS. On average, research analysts expect that TG Therapeutics will post -0.12 EPS for the current year.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a filing with the SEC, which is available through this link. 9.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of TG Therapeutics by 13.3% in the third quarter. Vanguard Group Inc. now owns 14,746,392 shares of the biopharmaceutical company's stock valued at $87,299,000 after purchasing an additional 1,725,560 shares during the last quarter. State Street Corp increased its holdings in shares of TG Therapeutics by 47.8% in the second quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company's stock valued at $60,500,000 after purchasing an additional 4,606,679 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of TG Therapeutics in the first quarter valued at about $157,187,000. BlackRock Inc. boosted its position in shares of TG Therapeutics by 12.1% in the second quarter. BlackRock Inc. now owns 9,917,463 shares of the biopharmaceutical company's stock valued at $246,350,000 after acquiring an additional 1,067,763 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of TG Therapeutics by 1.4% in the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company's stock valued at $53,627,000 after acquiring an additional 43,290 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.